Considerations for Managing Clinical Trials and Regulatory Filing Strategy During COVID-19

Apr 15, 2021

Posted by Certara

Using Type 9 NDA Designation to Accelerate Multiple Approvals for Your Drug Product

Apr 15, 2021

Posted by Certara

Implementing eCTD Through Outsourcing

Apr 08, 2021

Posted by Certara

Simcyp PBPK for Drug-Drug Interactions (DDIs): A Regulatory Imperative

Apr 08, 2021

Posted by Certara

Innovative Financing for Novel Therapies

Apr 08, 2021

Posted by Certara

The Escalating U.S. Policy Environment

Apr 06, 2021

Posted by Certara

Key Trends in US Specialty Pharmacy

Apr 06, 2021

Posted by Certara

The Rise of Cost Effectiveness Considerations in the US

Apr 06, 2021

Posted by Certara

The Effects of COVID-19 on Stakeholder Engagement & Value Communication: Preparing for the New Normal

Apr 06, 2021

Posted by Certara

“Where do I start?”: Strategies for selecting the first dose for human clinical trials

Apr 06, 2021

Posted by Certara